Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset

Roche commits to lean-mass preservation with Hanmi obesity deal

For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.